Kathleen Hogan
Medical · Houston, TXNPI 1366601437
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,331 of the $25,671 with a category attached, or 79.2%. It is spread thinly across 38 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $8,089, 3.8 times the $2,116 reported in 2021. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,114 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Regeneron Healthcare Solutions, Inc.$3K
- Johnson & Johnson$2K
- Dermavant Sciences, Inc.$2K
- Regeneron$1K
- Sanofi$1K
- plus $12K from 32 others
What the payments were for
- Consulting fees$4,21916%
- Travel & lodging$70%
- Food & beverage$20,33179%
- Education$1,1154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,671 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 48 | $867 |
| Clobetasol Propionate | 12 | $503 |
| ValacyclovirValacyclovir Hcl | 16 | $354 |
| Triamcinolone Acetonide | 37 | $329 |
| CiclopiroxCiclopirox Olamine | 16 | $311 |
| Clindamycin Phosphate | 12 | $303 |
| Mupirocin | 28 | $235 |
| Doxycycline Hyclate | 14 | $218 |
| Hydroxyzine Hcl | 20 | $137 |
| Minoxidil | 15 | $123 |
| Hydrocortisone | 19 | $120 |
| Fluconazole | 12 | $82 |
Paid to pharmacies, not to this prescriber.
Other medical in Houston
- Olga RodziyenskaHouston$65K
- Omni McCluneyHouston$18K
- Carl MayberryHouston$18K
- Carley BuddenbaumHouston$16K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.